-
Expansion of the neocortex and protection from neurodegeneration by in vivo transient reprogramming
Shen, Yi-Ru et al. Cell Stem Cell (2024). DOI:10.1016/j.stem.2024.09.013
-
Soluble mutant huntingtin drives early human pathogenesis in Huntington’s disease.
Miguez, A., Gomis, C., Vila, C. et al. Cell. Mol. Life Sci. 80, 238 (2023). https://doi.org/10.1007/s00018-023-04882-w
-
Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV).
Sánchez-Guijo, F., Avendaño-Solá, C., Badimón, L. et al. Bone Marrow Transplant 58, 727–728 (2023). https://doi.org/10.1038/s41409-023-01962-0
-
Hyaluronic acid-based bioink improves the differentiation and network formation of neural progenitor cells.
Pereira I, Lopez-Martinez MJ, Villasante A, Introna C, Tornero D, Canals JM, Samitier J. Front Bioeng Biotechnol. 2023 Mar 3;11:1110547. doi: 10.3389/fbioe.2023.1110547.
-
Ikzf1 as a novel regulator of microglial homeostasis in inflammation and neurodegeneration.
Ballasch I, García-García E, Vila C, Pérez-González A, Sancho-Balsells A, Fernández J, Soto D, Puigdellívol M, Gasull X, Alberch J, Rodríguez MJ, Canals JM, Giralt A. Brain Behav Immun. 2023 Mar;109:144-161. doi: 10.1016/j.bbi.2023.01.016.
-
Tbr1 Misexpression Alters Neuronal Development in the Cerebral Cortex.
Crespo I, Pignatelli J, Kinare V, Méndez-Gómez HR, Esgleas M, Román MJ, Canals JM, Tole S, Vicario C. Mol Neurobiol. 2022 Sep;59(9):5750-5765. doi: 10.1007/s12035-022-02936-x.
-
Standardization of Cell Culture Conditions and Routine Genomic Screening under a Quality Management System Leads to Reduced Genomic Instability in hPSCs.
Molina-Ruiz FJ, Introna C, Bombau G, Galofre M, Canals JM. Cells. 2022 Jun 21;11(13):1984. doi: 10.3390/cells11131984.
-
Translating cell therapies for neurodegenerative diseases: Huntington's disease as a model disorder.
Rosser AE, Busse ME, Gray WP, Badin RA, Perrier AL, Wheelock V, Cozzi E, Martin UP, Salado-Manzano C, Mills LJ, Drew C, Goldman SA, Canals JM, Thompson LM. Brain. 2022 Jun 3;145(5):1584-1597. doi: 10.1093/brain/awac086.
-
Human embryonic mesenchymal lung-conditioned medium promotes differentiation to myofibroblast and loss of stemness phenotype in lung adenocarcinoma cell lines.
Canals J, Navarro A, Vila C, Canals JM, Díaz T, Acosta-Plasencia M, Cros-Font C, Han B, He Y, Monzó M. J Exp Clin Cancer Res 41, 37 (2022). https://doi.org/10.1186/s13046-021-02206-z
-
Cell Therapy for Huntington's Disease: Learning from Failure.
Rosser AE, Busse M, Aron Badin R, Canals JM, Wheelock V, Perrier AL, Gray W, Thompson L, Goldman S. Mov Disord. 2021 Mar;36(3):787-788. doi: 10.1002/mds.28503.
-
Stem Cells for Huntington's Disease (SC4HD): An International Consortium to Facilitate Stem Cell-Based Therapy for Huntington's Disease.
SC4HD Consortium. J Huntingtons Dis. 2021;10(2):221-226. doi: 10.3233/JHD-210473.
-
Effect of Intranodally Administered Dendritic Cell-Based HIV Vaccine in Combination With Pegylated Interferon α-2a on Viral Control Following ART Discontinuation: A Phase 2A Randomized Clinical Trial.
Leal L, Couto E, Sánchez-Palomino S, Climent N, Fernández I, Miralles L, Romero Y, González T, Maleno MJ, Paño B, Pich J, Nicolau C, Gatell JM, Plana M, García F. Front Immunol. 2021 Nov 11;12:767370. doi: 10.3389/fimmu.2021.767370.
-
Decreased Myocyte Enhancer Factor 2 Levels in the Hippocampus of Huntington's Disease Mice Are Related to Cognitive Dysfunction.
Vidal-Sancho L, Fernández-García S, Solés-Tarrés I, Alberch J, Xifró X. Mol Neurobiol. 2020 57(11):4549-4562.
-
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19 + Relapsed/Refractory Malignancies.
Ortíz-Maldonado V, Rives S, Castellà M, Alonso-Saladrigues A, Benítez-Ribas D, Caballero-Baños M, Baumann T, Cid J, Garcia-Rey E, Llanos C, Torrebadell M, Villamor N, Giné E, Díaz-Beyá M, Guardia L, Montoro M, Català A, Faura A, González EA, Español-Rego M, Klein-González N, Alsina L, Castro P, Jordan I, Fernández S, Ramos F, Suñé G, Perpiñá U, Canals JM, Lozano M, Trias E, Scalise A, Varea S, Sáez-Peñataro J, Torres F, Calvo G, Esteve J, Urbano-Ispizua Á, Juan M, Delgado J. Mol Ther. 2021 Feb 3;29(2):636-644. doi: 10.1016/j.ymthe.2020.09.027.
-
Is the Immunological Response a Bottleneck for Cell Therapy in Neurodegenerative Diseases?
Salado-Manzano C, Perpiña U, Straccia M, Molina-Ruiz FJ, Cozzi E, Rosser AE, Canals JM. Front Cell Neurosci. 2020 Aug 11;14:250. doi: 10.3389/fncel.2020.00250.
-
Advanced Non-animal Models in Biomedical Research – Immunogenicity testing for advanced therapy medicinal products.
Canals, J. M., Romania, P., Belio-Mairal P., Nic, M., Dibusz, K., Novotny, T., Busquet, F., Rossi, F., Straccia, M., Daskalopoulos, E. P., and Gribaldo, L. EUR 30334/4 EN, Publications Office of the European Union, Luxembourg, 2022, ISBN 978-92-76-49091-3. doi:10.2760/7190, JRC126997.
-
Advanced Non-animal Models in Biomedical Research - Autoimmune Diseases.
Juan, M., Canals, J.M., Belio-Mairal, P., Nic, M., Dibusz, K., Novotny, T., Busquet, F., Rossi, F., Gastaldello, A., Gribaldo, L., Straccia, M., Dura, A. and Whelan, M. EUR 30334/6 EN, Publications Office of the European Union, Luxembourg, 2022, ISBN 978-92-76-58966-2
-
Advanced Therapy Medicinal Products.
Meij P., Canals, J.M., Lowery M., Scott M. LERU Briefing paper. 2019 September.